1178564-27-6 Usage
General Description
4-(4-Chloro-7-(methylsulfonyl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine is a chemical compound with potential pharmacological properties. It is a morpholine derivative with a chloro and methylsulfonyl group attached to a pyrrolopyrimidine ring. 4-(4-Chloro-7-(methylsulfonyl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-2-yl)morpholine has been studied for its potential use in the treatment of certain medical conditions, including cancer and inflammatory disorders. Its unique structure and pharmacological activity make it a promising candidate for further research and development in the field of medicinal chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 1178564-27-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,7,8,5,6 and 4 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1178564-27:
(9*1)+(8*1)+(7*7)+(6*8)+(5*5)+(4*6)+(3*4)+(2*2)+(1*7)=186
186 % 10 = 6
So 1178564-27-6 is a valid CAS Registry Number.
1178564-27-6Relevant articles and documents
Discovery and biological activity of a novel class i PI3K inhibitor, CH5132799
Ohwada, Jun,Ebiike, Hirosato,Kawada, Hatsuo,Tsukazaki, Masao,Nakamura, Mitsuaki,Miyazaki, Takuya,Morikami, Kenji,Yoshinari, Kiyoshi,Yoshida, Miyuki,Kondoh, Osamu,Kuramoto, Shino,Ogawa, Kotaro,Aoki, Yuko,Shimma, Nobuo
, p. 1767 - 1772 (2011/05/05)
Phosphatidylinositol 3-kinase (PI3K) is a lipid kinase and a promising therapeutic target for cancer. Using structure-based drug design (SBDD), we have identified novel PI3K inhibitors with a dihydropyrrolopyrimidine skeleton. Metabolic stability of the first lead series was drastically improved by replacing phenol with aminopyrimidine moiety. CH5132799, a novel class I PI3K inhibitor, exhibited a strong inhibitory activity especially against PI3Kα (IC50 = 0.014 μM). In human tumor cell lines with PI3K pathway activation, CH5132799 showed potent antiproliferative activity. CH5132799 is orally available and showed significant antitumor activity in PI3K pathway-activated human cancer xenograft models in mice.
